Global Pneumonia Vaccine Market Growth 2025-2031
The global Pneumonia Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Pneumonia Vaccine Industry Forecast” looks at past sales and reviews total world Pneumonia Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Pneumonia Vaccine sales for 2025 through 2031. With Pneumonia Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumonia Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pneumonia Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumonia Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pneumonia Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumonia Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumonia Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pneumonia Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Pneumonia Vaccine market?
What factors are driving Pneumonia Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumonia Vaccine market opportunities vary by end market size?
How does Pneumonia Vaccine break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Pneumonia Vaccine Industry Forecast” looks at past sales and reviews total world Pneumonia Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Pneumonia Vaccine sales for 2025 through 2031. With Pneumonia Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumonia Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pneumonia Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumonia Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pneumonia Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumonia Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumonia Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pneumonia Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pneumococcal Conjugate Vaccine (PCV13)
- Pneumococcal Polysaccharide Vaccine (PPSV23)
- Other
- Pneumonia
- Meningitis
- Sepsis
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer Inc.
- Glaxosmithkline Plc.
- Merck & Co., Inc.
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Johnson & Johnson
- Astellas Pharma Inc.
- Astrazeneca Plc.
- CSL Limited
- Emergent Biosolutions
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Zhifei Biologic
What is the 10-year outlook for the global Pneumonia Vaccine market?
What factors are driving Pneumonia Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumonia Vaccine market opportunities vary by end market size?
How does Pneumonia Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pneumonia Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pneumonia Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pneumonia Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Pneumonia Vaccine Segment by Type
2.2.1 Pneumococcal Conjugate Vaccine (PCV13)
2.2.2 Pneumococcal Polysaccharide Vaccine (PPSV23)
2.2.3 Other
2.3 Pneumonia Vaccine Sales by Type
2.3.1 Global Pneumonia Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Pneumonia Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pneumonia Vaccine Sale Price by Type (2020-2025)
2.4 Pneumonia Vaccine Segment by Application
2.4.1 Pneumonia
2.4.2 Meningitis
2.4.3 Sepsis
2.5 Pneumonia Vaccine Sales by Application
2.5.1 Global Pneumonia Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Pneumonia Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pneumonia Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Pneumonia Vaccine Breakdown Data by Company
3.1.1 Global Pneumonia Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Pneumonia Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Pneumonia Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Pneumonia Vaccine Revenue by Company (2020-2025)
3.2.2 Global Pneumonia Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Pneumonia Vaccine Sale Price by Company
3.4 Key Manufacturers Pneumonia Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pneumonia Vaccine Product Location Distribution
3.4.2 Players Pneumonia Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PNEUMONIA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pneumonia Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Pneumonia Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pneumonia Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pneumonia Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Pneumonia Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pneumonia Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pneumonia Vaccine Sales Growth
4.4 APAC Pneumonia Vaccine Sales Growth
4.5 Europe Pneumonia Vaccine Sales Growth
4.6 Middle East & Africa Pneumonia Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pneumonia Vaccine Sales by Country
5.1.1 Americas Pneumonia Vaccine Sales by Country (2020-2025)
5.1.2 Americas Pneumonia Vaccine Revenue by Country (2020-2025)
5.2 Americas Pneumonia Vaccine Sales by Type (2020-2025)
5.3 Americas Pneumonia Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pneumonia Vaccine Sales by Region
6.1.1 APAC Pneumonia Vaccine Sales by Region (2020-2025)
6.1.2 APAC Pneumonia Vaccine Revenue by Region (2020-2025)
6.2 APAC Pneumonia Vaccine Sales by Type (2020-2025)
6.3 APAC Pneumonia Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pneumonia Vaccine by Country
7.1.1 Europe Pneumonia Vaccine Sales by Country (2020-2025)
7.1.2 Europe Pneumonia Vaccine Revenue by Country (2020-2025)
7.2 Europe Pneumonia Vaccine Sales by Type (2020-2025)
7.3 Europe Pneumonia Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pneumonia Vaccine by Country
8.1.1 Middle East & Africa Pneumonia Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pneumonia Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Pneumonia Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Pneumonia Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pneumonia Vaccine
10.3 Manufacturing Process Analysis of Pneumonia Vaccine
10.4 Industry Chain Structure of Pneumonia Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pneumonia Vaccine Distributors
11.3 Pneumonia Vaccine Customer
12 WORLD FORECAST REVIEW FOR PNEUMONIA VACCINE BY GEOGRAPHIC REGION
12.1 Global Pneumonia Vaccine Market Size Forecast by Region
12.1.1 Global Pneumonia Vaccine Forecast by Region (2026-2031)
12.1.2 Global Pneumonia Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pneumonia Vaccine Forecast by Type (2026-2031)
12.7 Global Pneumonia Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer Inc.
13.1.1 Pfizer Inc. Company Information
13.1.2 Pfizer Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Inc. Main Business Overview
13.1.5 Pfizer Inc. Latest Developments
13.2 Glaxosmithkline Plc.
13.2.1 Glaxosmithkline Plc. Company Information
13.2.2 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolios and Specifications
13.2.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Glaxosmithkline Plc. Main Business Overview
13.2.5 Glaxosmithkline Plc. Latest Developments
13.3 Merck & Co., Inc.
13.3.1 Merck & Co., Inc. Company Information
13.3.2 Merck & Co., Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.3.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck & Co., Inc. Main Business Overview
13.3.5 Merck & Co., Inc. Latest Developments
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Information
13.4.2 Sanofi Pasteur Pneumonia Vaccine Product Portfolios and Specifications
13.4.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Pasteur Main Business Overview
13.4.5 Sanofi Pasteur Latest Developments
13.5 Serum Institute of India Pvt. Ltd.
13.5.1 Serum Institute of India Pvt. Ltd. Company Information
13.5.2 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolios and Specifications
13.5.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Serum Institute of India Pvt. Ltd. Main Business Overview
13.5.5 Serum Institute of India Pvt. Ltd. Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Pneumonia Vaccine Product Portfolios and Specifications
13.6.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Astellas Pharma Inc.
13.7.1 Astellas Pharma Inc. Company Information
13.7.2 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.7.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Astellas Pharma Inc. Main Business Overview
13.7.5 Astellas Pharma Inc. Latest Developments
13.8 Astrazeneca Plc.
13.8.1 Astrazeneca Plc. Company Information
13.8.2 Astrazeneca Plc. Pneumonia Vaccine Product Portfolios and Specifications
13.8.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Astrazeneca Plc. Main Business Overview
13.8.5 Astrazeneca Plc. Latest Developments
13.9 CSL Limited
13.9.1 CSL Limited Company Information
13.9.2 CSL Limited Pneumonia Vaccine Product Portfolios and Specifications
13.9.3 CSL Limited Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 CSL Limited Main Business Overview
13.9.5 CSL Limited Latest Developments
13.10 Emergent Biosolutions
13.10.1 Emergent Biosolutions Company Information
13.10.2 Emergent Biosolutions Pneumonia Vaccine Product Portfolios and Specifications
13.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Emergent Biosolutions Main Business Overview
13.10.5 Emergent Biosolutions Latest Developments
13.11 Walvax Biotechnology
13.11.1 Walvax Biotechnology Company Information
13.11.2 Walvax Biotechnology Pneumonia Vaccine Product Portfolios and Specifications
13.11.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Walvax Biotechnology Main Business Overview
13.11.5 Walvax Biotechnology Latest Developments
13.12 Royal (Wuxi) Bio-Pharmaceutical
13.12.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.12.2 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolios and Specifications
13.12.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.12.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.13 Zhifei Biologic
13.13.1 Zhifei Biologic Company Information
13.13.2 Zhifei Biologic Pneumonia Vaccine Product Portfolios and Specifications
13.13.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Zhifei Biologic Main Business Overview
13.13.5 Zhifei Biologic Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pneumonia Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pneumonia Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pneumonia Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Pneumonia Vaccine Segment by Type
2.2.1 Pneumococcal Conjugate Vaccine (PCV13)
2.2.2 Pneumococcal Polysaccharide Vaccine (PPSV23)
2.2.3 Other
2.3 Pneumonia Vaccine Sales by Type
2.3.1 Global Pneumonia Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Pneumonia Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pneumonia Vaccine Sale Price by Type (2020-2025)
2.4 Pneumonia Vaccine Segment by Application
2.4.1 Pneumonia
2.4.2 Meningitis
2.4.3 Sepsis
2.5 Pneumonia Vaccine Sales by Application
2.5.1 Global Pneumonia Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Pneumonia Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pneumonia Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Pneumonia Vaccine Breakdown Data by Company
3.1.1 Global Pneumonia Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Pneumonia Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Pneumonia Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Pneumonia Vaccine Revenue by Company (2020-2025)
3.2.2 Global Pneumonia Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Pneumonia Vaccine Sale Price by Company
3.4 Key Manufacturers Pneumonia Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pneumonia Vaccine Product Location Distribution
3.4.2 Players Pneumonia Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PNEUMONIA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pneumonia Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Pneumonia Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pneumonia Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pneumonia Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Pneumonia Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pneumonia Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pneumonia Vaccine Sales Growth
4.4 APAC Pneumonia Vaccine Sales Growth
4.5 Europe Pneumonia Vaccine Sales Growth
4.6 Middle East & Africa Pneumonia Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pneumonia Vaccine Sales by Country
5.1.1 Americas Pneumonia Vaccine Sales by Country (2020-2025)
5.1.2 Americas Pneumonia Vaccine Revenue by Country (2020-2025)
5.2 Americas Pneumonia Vaccine Sales by Type (2020-2025)
5.3 Americas Pneumonia Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pneumonia Vaccine Sales by Region
6.1.1 APAC Pneumonia Vaccine Sales by Region (2020-2025)
6.1.2 APAC Pneumonia Vaccine Revenue by Region (2020-2025)
6.2 APAC Pneumonia Vaccine Sales by Type (2020-2025)
6.3 APAC Pneumonia Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pneumonia Vaccine by Country
7.1.1 Europe Pneumonia Vaccine Sales by Country (2020-2025)
7.1.2 Europe Pneumonia Vaccine Revenue by Country (2020-2025)
7.2 Europe Pneumonia Vaccine Sales by Type (2020-2025)
7.3 Europe Pneumonia Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pneumonia Vaccine by Country
8.1.1 Middle East & Africa Pneumonia Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pneumonia Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Pneumonia Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Pneumonia Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pneumonia Vaccine
10.3 Manufacturing Process Analysis of Pneumonia Vaccine
10.4 Industry Chain Structure of Pneumonia Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pneumonia Vaccine Distributors
11.3 Pneumonia Vaccine Customer
12 WORLD FORECAST REVIEW FOR PNEUMONIA VACCINE BY GEOGRAPHIC REGION
12.1 Global Pneumonia Vaccine Market Size Forecast by Region
12.1.1 Global Pneumonia Vaccine Forecast by Region (2026-2031)
12.1.2 Global Pneumonia Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pneumonia Vaccine Forecast by Type (2026-2031)
12.7 Global Pneumonia Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer Inc.
13.1.1 Pfizer Inc. Company Information
13.1.2 Pfizer Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Inc. Main Business Overview
13.1.5 Pfizer Inc. Latest Developments
13.2 Glaxosmithkline Plc.
13.2.1 Glaxosmithkline Plc. Company Information
13.2.2 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolios and Specifications
13.2.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Glaxosmithkline Plc. Main Business Overview
13.2.5 Glaxosmithkline Plc. Latest Developments
13.3 Merck & Co., Inc.
13.3.1 Merck & Co., Inc. Company Information
13.3.2 Merck & Co., Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.3.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck & Co., Inc. Main Business Overview
13.3.5 Merck & Co., Inc. Latest Developments
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Information
13.4.2 Sanofi Pasteur Pneumonia Vaccine Product Portfolios and Specifications
13.4.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Pasteur Main Business Overview
13.4.5 Sanofi Pasteur Latest Developments
13.5 Serum Institute of India Pvt. Ltd.
13.5.1 Serum Institute of India Pvt. Ltd. Company Information
13.5.2 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolios and Specifications
13.5.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Serum Institute of India Pvt. Ltd. Main Business Overview
13.5.5 Serum Institute of India Pvt. Ltd. Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Pneumonia Vaccine Product Portfolios and Specifications
13.6.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Astellas Pharma Inc.
13.7.1 Astellas Pharma Inc. Company Information
13.7.2 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolios and Specifications
13.7.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Astellas Pharma Inc. Main Business Overview
13.7.5 Astellas Pharma Inc. Latest Developments
13.8 Astrazeneca Plc.
13.8.1 Astrazeneca Plc. Company Information
13.8.2 Astrazeneca Plc. Pneumonia Vaccine Product Portfolios and Specifications
13.8.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Astrazeneca Plc. Main Business Overview
13.8.5 Astrazeneca Plc. Latest Developments
13.9 CSL Limited
13.9.1 CSL Limited Company Information
13.9.2 CSL Limited Pneumonia Vaccine Product Portfolios and Specifications
13.9.3 CSL Limited Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 CSL Limited Main Business Overview
13.9.5 CSL Limited Latest Developments
13.10 Emergent Biosolutions
13.10.1 Emergent Biosolutions Company Information
13.10.2 Emergent Biosolutions Pneumonia Vaccine Product Portfolios and Specifications
13.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Emergent Biosolutions Main Business Overview
13.10.5 Emergent Biosolutions Latest Developments
13.11 Walvax Biotechnology
13.11.1 Walvax Biotechnology Company Information
13.11.2 Walvax Biotechnology Pneumonia Vaccine Product Portfolios and Specifications
13.11.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Walvax Biotechnology Main Business Overview
13.11.5 Walvax Biotechnology Latest Developments
13.12 Royal (Wuxi) Bio-Pharmaceutical
13.12.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.12.2 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolios and Specifications
13.12.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.12.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.13 Zhifei Biologic
13.13.1 Zhifei Biologic Company Information
13.13.2 Zhifei Biologic Pneumonia Vaccine Product Portfolios and Specifications
13.13.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Zhifei Biologic Main Business Overview
13.13.5 Zhifei Biologic Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pneumonia Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Pneumonia Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Pneumococcal Conjugate Vaccine (PCV13)
Table 4. Major Players of Pneumococcal Polysaccharide Vaccine (PPSV23)
Table 5. Major Players of Other
Table 6. Global Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 7. Global Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Table 8. Global Pneumonia Vaccine Revenue by Type (2020-2025) & ($ million)
Table 9. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2025)
Table 10. Global Pneumonia Vaccine Sale Price by Type (2020-2025) & (USD/Dose)
Table 11. Global Pneumonia Vaccine Sale by Application (2020-2025) & (K Doses)
Table 12. Global Pneumonia Vaccine Sale Market Share by Application (2020-2025)
Table 13. Global Pneumonia Vaccine Revenue by Application (2020-2025) & ($ million)
Table 14. Global Pneumonia Vaccine Revenue Market Share by Application (2020-2025)
Table 15. Global Pneumonia Vaccine Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global Pneumonia Vaccine Sales by Company (2020-2025) & (K Doses)
Table 17. Global Pneumonia Vaccine Sales Market Share by Company (2020-2025)
Table 18. Global Pneumonia Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Pneumonia Vaccine Revenue Market Share by Company (2020-2025)
Table 20. Global Pneumonia Vaccine Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers Pneumonia Vaccine Producing Area Distribution and Sales Area
Table 22. Players Pneumonia Vaccine Products Offered
Table 23. Pneumonia Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Pneumonia Vaccine Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global Pneumonia Vaccine Sales Market Share Geographic Region (2020-2025)
Table 28. Global Pneumonia Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Pneumonia Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Pneumonia Vaccine Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global Pneumonia Vaccine Sales Market Share by Country/Region (2020-2025)
Table 32. Global Pneumonia Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Pneumonia Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 35. Americas Pneumonia Vaccine Sales Market Share by Country (2020-2025)
Table 36. Americas Pneumonia Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 38. Americas Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 39. APAC Pneumonia Vaccine Sales by Region (2020-2025) & (K Doses)
Table 40. APAC Pneumonia Vaccine Sales Market Share by Region (2020-2025)
Table 41. APAC Pneumonia Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. APAC Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 44. Europe Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 45. Europe Pneumonia Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 47. Europe Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Middle East & Africa Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of Pneumonia Vaccine
Table 53. Key Market Challenges & Risks of Pneumonia Vaccine
Table 54. Key Industry Trends of Pneumonia Vaccine
Table 55. Pneumonia Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Pneumonia Vaccine Distributors List
Table 58. Pneumonia Vaccine Customer List
Table 59. Global Pneumonia Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 60. Global Pneumonia Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 62. Americas Pneumonia Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Pneumonia Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 64. APAC Pneumonia Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 66. Europe Pneumonia Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa Pneumonia Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Pneumonia Vaccine Sales Forecast by Type (2026-2031) & (K Doses)
Table 70. Global Pneumonia Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Pneumonia Vaccine Sales Forecast by Application (2026-2031) & (K Doses)
Table 72. Global Pneumonia Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 75. Pfizer Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. Pfizer Inc. Main Business
Table 77. Pfizer Inc. Latest Developments
Table 78. Glaxosmithkline Plc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolios and Specifications
Table 80. Glaxosmithkline Plc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Glaxosmithkline Plc. Main Business
Table 82. Glaxosmithkline Plc. Latest Developments
Table 83. Merck & Co., Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck & Co., Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 85. Merck & Co., Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Merck & Co., Inc. Main Business
Table 87. Merck & Co., Inc. Latest Developments
Table 88. Sanofi Pasteur Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Pasteur Pneumonia Vaccine Product Portfolios and Specifications
Table 90. Sanofi Pasteur Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Sanofi Pasteur Main Business
Table 92. Sanofi Pasteur Latest Developments
Table 93. Serum Institute of India Pvt. Ltd. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolios and Specifications
Table 95. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Serum Institute of India Pvt. Ltd. Main Business
Table 97. Serum Institute of India Pvt. Ltd. Latest Developments
Table 98. Johnson & Johnson Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Johnson & Johnson Pneumonia Vaccine Product Portfolios and Specifications
Table 100. Johnson & Johnson Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Johnson & Johnson Main Business
Table 102. Johnson & Johnson Latest Developments
Table 103. Astellas Pharma Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 105. Astellas Pharma Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Astellas Pharma Inc. Main Business
Table 107. Astellas Pharma Inc. Latest Developments
Table 108. Astrazeneca Plc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Astrazeneca Plc. Pneumonia Vaccine Product Portfolios and Specifications
Table 110. Astrazeneca Plc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Astrazeneca Plc. Main Business
Table 112. Astrazeneca Plc. Latest Developments
Table 113. CSL Limited Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. CSL Limited Pneumonia Vaccine Product Portfolios and Specifications
Table 115. CSL Limited Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. CSL Limited Main Business
Table 117. CSL Limited Latest Developments
Table 118. Emergent Biosolutions Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Emergent Biosolutions Pneumonia Vaccine Product Portfolios and Specifications
Table 120. Emergent Biosolutions Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Emergent Biosolutions Main Business
Table 122. Emergent Biosolutions Latest Developments
Table 123. Walvax Biotechnology Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Walvax Biotechnology Pneumonia Vaccine Product Portfolios and Specifications
Table 125. Walvax Biotechnology Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 126. Walvax Biotechnology Main Business
Table 127. Walvax Biotechnology Latest Developments
Table 128. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolios and Specifications
Table 130. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 131. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 132. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 133. Zhifei Biologic Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Zhifei Biologic Pneumonia Vaccine Product Portfolios and Specifications
Table 135. Zhifei Biologic Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 136. Zhifei Biologic Main Business
Table 137. Zhifei Biologic Latest Developments
Table 1. Pneumonia Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Pneumonia Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Pneumococcal Conjugate Vaccine (PCV13)
Table 4. Major Players of Pneumococcal Polysaccharide Vaccine (PPSV23)
Table 5. Major Players of Other
Table 6. Global Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 7. Global Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Table 8. Global Pneumonia Vaccine Revenue by Type (2020-2025) & ($ million)
Table 9. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2025)
Table 10. Global Pneumonia Vaccine Sale Price by Type (2020-2025) & (USD/Dose)
Table 11. Global Pneumonia Vaccine Sale by Application (2020-2025) & (K Doses)
Table 12. Global Pneumonia Vaccine Sale Market Share by Application (2020-2025)
Table 13. Global Pneumonia Vaccine Revenue by Application (2020-2025) & ($ million)
Table 14. Global Pneumonia Vaccine Revenue Market Share by Application (2020-2025)
Table 15. Global Pneumonia Vaccine Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global Pneumonia Vaccine Sales by Company (2020-2025) & (K Doses)
Table 17. Global Pneumonia Vaccine Sales Market Share by Company (2020-2025)
Table 18. Global Pneumonia Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Pneumonia Vaccine Revenue Market Share by Company (2020-2025)
Table 20. Global Pneumonia Vaccine Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers Pneumonia Vaccine Producing Area Distribution and Sales Area
Table 22. Players Pneumonia Vaccine Products Offered
Table 23. Pneumonia Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Pneumonia Vaccine Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global Pneumonia Vaccine Sales Market Share Geographic Region (2020-2025)
Table 28. Global Pneumonia Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Pneumonia Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Pneumonia Vaccine Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global Pneumonia Vaccine Sales Market Share by Country/Region (2020-2025)
Table 32. Global Pneumonia Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Pneumonia Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 35. Americas Pneumonia Vaccine Sales Market Share by Country (2020-2025)
Table 36. Americas Pneumonia Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 38. Americas Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 39. APAC Pneumonia Vaccine Sales by Region (2020-2025) & (K Doses)
Table 40. APAC Pneumonia Vaccine Sales Market Share by Region (2020-2025)
Table 41. APAC Pneumonia Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. APAC Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 44. Europe Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 45. Europe Pneumonia Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 47. Europe Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa Pneumonia Vaccine Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Pneumonia Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Middle East & Africa Pneumonia Vaccine Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of Pneumonia Vaccine
Table 53. Key Market Challenges & Risks of Pneumonia Vaccine
Table 54. Key Industry Trends of Pneumonia Vaccine
Table 55. Pneumonia Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Pneumonia Vaccine Distributors List
Table 58. Pneumonia Vaccine Customer List
Table 59. Global Pneumonia Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 60. Global Pneumonia Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 62. Americas Pneumonia Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Pneumonia Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 64. APAC Pneumonia Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 66. Europe Pneumonia Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Pneumonia Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa Pneumonia Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Pneumonia Vaccine Sales Forecast by Type (2026-2031) & (K Doses)
Table 70. Global Pneumonia Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Pneumonia Vaccine Sales Forecast by Application (2026-2031) & (K Doses)
Table 72. Global Pneumonia Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 75. Pfizer Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. Pfizer Inc. Main Business
Table 77. Pfizer Inc. Latest Developments
Table 78. Glaxosmithkline Plc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolios and Specifications
Table 80. Glaxosmithkline Plc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. Glaxosmithkline Plc. Main Business
Table 82. Glaxosmithkline Plc. Latest Developments
Table 83. Merck & Co., Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck & Co., Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 85. Merck & Co., Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Merck & Co., Inc. Main Business
Table 87. Merck & Co., Inc. Latest Developments
Table 88. Sanofi Pasteur Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Pasteur Pneumonia Vaccine Product Portfolios and Specifications
Table 90. Sanofi Pasteur Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Sanofi Pasteur Main Business
Table 92. Sanofi Pasteur Latest Developments
Table 93. Serum Institute of India Pvt. Ltd. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolios and Specifications
Table 95. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Serum Institute of India Pvt. Ltd. Main Business
Table 97. Serum Institute of India Pvt. Ltd. Latest Developments
Table 98. Johnson & Johnson Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Johnson & Johnson Pneumonia Vaccine Product Portfolios and Specifications
Table 100. Johnson & Johnson Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Johnson & Johnson Main Business
Table 102. Johnson & Johnson Latest Developments
Table 103. Astellas Pharma Inc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma Inc. Pneumonia Vaccine Product Portfolios and Specifications
Table 105. Astellas Pharma Inc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Astellas Pharma Inc. Main Business
Table 107. Astellas Pharma Inc. Latest Developments
Table 108. Astrazeneca Plc. Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Astrazeneca Plc. Pneumonia Vaccine Product Portfolios and Specifications
Table 110. Astrazeneca Plc. Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Astrazeneca Plc. Main Business
Table 112. Astrazeneca Plc. Latest Developments
Table 113. CSL Limited Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. CSL Limited Pneumonia Vaccine Product Portfolios and Specifications
Table 115. CSL Limited Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. CSL Limited Main Business
Table 117. CSL Limited Latest Developments
Table 118. Emergent Biosolutions Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Emergent Biosolutions Pneumonia Vaccine Product Portfolios and Specifications
Table 120. Emergent Biosolutions Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Emergent Biosolutions Main Business
Table 122. Emergent Biosolutions Latest Developments
Table 123. Walvax Biotechnology Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Walvax Biotechnology Pneumonia Vaccine Product Portfolios and Specifications
Table 125. Walvax Biotechnology Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 126. Walvax Biotechnology Main Business
Table 127. Walvax Biotechnology Latest Developments
Table 128. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolios and Specifications
Table 130. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 131. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 132. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 133. Zhifei Biologic Basic Information, Pneumonia Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. Zhifei Biologic Pneumonia Vaccine Product Portfolios and Specifications
Table 135. Zhifei Biologic Pneumonia Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 136. Zhifei Biologic Main Business
Table 137. Zhifei Biologic Latest Developments
LIST OF FIGURES
Figure 1. Picture of Pneumonia Vaccine
Figure 2. Pneumonia Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pneumonia Vaccine Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Pneumonia Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Pneumonia Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Pneumonia Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Pneumonia Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Pneumococcal Conjugate Vaccine (PCV13)
Figure 12. Product Picture of Pneumococcal Polysaccharide Vaccine (PPSV23)
Figure 13. Product Picture of Other
Figure 14. Global Pneumonia Vaccine Sales Market Share by Type in 2025
Figure 15. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2025)
Figure 16. Pneumonia Vaccine Consumed in Pneumonia
Figure 17. Global Pneumonia Vaccine Market: Pneumonia (2020-2025) & (K Doses)
Figure 18. Pneumonia Vaccine Consumed in Meningitis
Figure 19. Global Pneumonia Vaccine Market: Meningitis (2020-2025) & (K Doses)
Figure 20. Pneumonia Vaccine Consumed in Sepsis
Figure 21. Global Pneumonia Vaccine Market: Sepsis (2020-2025) & (K Doses)
Figure 22. Global Pneumonia Vaccine Sale Market Share by Application (2024)
Figure 23. Global Pneumonia Vaccine Revenue Market Share by Application in 2025
Figure 24. Pneumonia Vaccine Sales by Company in 2025 (K Doses)
Figure 25. Global Pneumonia Vaccine Sales Market Share by Company in 2025
Figure 26. Pneumonia Vaccine Revenue by Company in 2025 ($ millions)
Figure 27. Global Pneumonia Vaccine Revenue Market Share by Company in 2025
Figure 28. Global Pneumonia Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Pneumonia Vaccine Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 31. Americas Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 32. APAC Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 33. APAC Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 34. Europe Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 35. Europe Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 38. Americas Pneumonia Vaccine Sales Market Share by Country in 2025
Figure 39. Americas Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Figure 40. Americas Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 41. Americas Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 42. United States Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Pneumonia Vaccine Sales Market Share by Region in 2025
Figure 47. APAC Pneumonia Vaccine Revenue Market Share by Region (2020-2025)
Figure 48. APAC Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 49. APAC Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 50. China Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. India Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Pneumonia Vaccine Sales Market Share by Country in 2025
Figure 58. Europe Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Figure 59. Europe Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 60. Europe Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 61. Germany Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. France Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Pneumonia Vaccine Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 69. Egypt Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Pneumonia Vaccine in 2025
Figure 75. Manufacturing Process Analysis of Pneumonia Vaccine
Figure 76. Industry Chain Structure of Pneumonia Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Pneumonia Vaccine Sales Market Forecast by Region (2026-2031)
Figure 79. Global Pneumonia Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Pneumonia Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Pneumonia Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Pneumonia Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Pneumonia Vaccine Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Pneumonia Vaccine
Figure 2. Pneumonia Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pneumonia Vaccine Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Pneumonia Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Pneumonia Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Pneumonia Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Pneumonia Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Pneumococcal Conjugate Vaccine (PCV13)
Figure 12. Product Picture of Pneumococcal Polysaccharide Vaccine (PPSV23)
Figure 13. Product Picture of Other
Figure 14. Global Pneumonia Vaccine Sales Market Share by Type in 2025
Figure 15. Global Pneumonia Vaccine Revenue Market Share by Type (2020-2025)
Figure 16. Pneumonia Vaccine Consumed in Pneumonia
Figure 17. Global Pneumonia Vaccine Market: Pneumonia (2020-2025) & (K Doses)
Figure 18. Pneumonia Vaccine Consumed in Meningitis
Figure 19. Global Pneumonia Vaccine Market: Meningitis (2020-2025) & (K Doses)
Figure 20. Pneumonia Vaccine Consumed in Sepsis
Figure 21. Global Pneumonia Vaccine Market: Sepsis (2020-2025) & (K Doses)
Figure 22. Global Pneumonia Vaccine Sale Market Share by Application (2024)
Figure 23. Global Pneumonia Vaccine Revenue Market Share by Application in 2025
Figure 24. Pneumonia Vaccine Sales by Company in 2025 (K Doses)
Figure 25. Global Pneumonia Vaccine Sales Market Share by Company in 2025
Figure 26. Pneumonia Vaccine Revenue by Company in 2025 ($ millions)
Figure 27. Global Pneumonia Vaccine Revenue Market Share by Company in 2025
Figure 28. Global Pneumonia Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Pneumonia Vaccine Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 31. Americas Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 32. APAC Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 33. APAC Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 34. Europe Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 35. Europe Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Pneumonia Vaccine Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa Pneumonia Vaccine Revenue 2020-2025 ($ millions)
Figure 38. Americas Pneumonia Vaccine Sales Market Share by Country in 2025
Figure 39. Americas Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Figure 40. Americas Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 41. Americas Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 42. United States Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Pneumonia Vaccine Sales Market Share by Region in 2025
Figure 47. APAC Pneumonia Vaccine Revenue Market Share by Region (2020-2025)
Figure 48. APAC Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 49. APAC Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 50. China Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. India Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Pneumonia Vaccine Sales Market Share by Country in 2025
Figure 58. Europe Pneumonia Vaccine Revenue Market Share by Country (2020-2025)
Figure 59. Europe Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 60. Europe Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 61. Germany Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. France Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Pneumonia Vaccine Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Pneumonia Vaccine Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Pneumonia Vaccine Sales Market Share by Application (2020-2025)
Figure 69. Egypt Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Pneumonia Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Pneumonia Vaccine in 2025
Figure 75. Manufacturing Process Analysis of Pneumonia Vaccine
Figure 76. Industry Chain Structure of Pneumonia Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Pneumonia Vaccine Sales Market Forecast by Region (2026-2031)
Figure 79. Global Pneumonia Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Pneumonia Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Pneumonia Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Pneumonia Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Pneumonia Vaccine Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Nasolacrimal Stents Market Growth 2023-2029
US$ 3,660.00
March 2023
94 pages
Global Alzheimer's Disease Therapeutics and Diagnostics Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
November 2024
106 pages
Global Food Allergy Diagnosis and Treatment Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
101 pages
Global CBCT Systems Market Growth 2024-2030
US$ 3,660.00
December 2024
116 pages
Global Veterinary Autogenous Vaccines Market Growth 2024-2030
US$ 3,660.00
December 2024
130 pages
